Enzymatica AB (FRA:EN9) GF Score: 36/100 (As of Jul. 09, 2026) — 28% Below Median


FRA:EN9 Enzymatica AB FRA:EN9
36 GF Score
Price €0.18
GF Value €0.16
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB GF Score?

Enzymatica AB FRA:EN9 -5.44% 36 GF Score is 36 as of Jul. 09, 2026, which is 28% below its 10-year median of 50.00. GuruFocus rates FRA:EN9 with a GF Score™ of 36/100 and a GF Value™ of €0.16 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Enzymatica AB has the GF Score of 36, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 1/10
3. Growth Rank : 1/10
4. GF Value Rank : 6/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Enzymatica AB might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Enzymatica AB  (FRA:EN9) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Enzymatica AB GF Score Related Terms

FRA:EN9 vs ZTS, UTHR: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzymatica AB GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's GF Score distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's GF Score falls into.


FRA:EN9
36GF Score
Enzymatica AB FRA:EN9
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 36 mean?
Enzymatica AB (FRA:EN9) has a GF Score of 36 as of Jul. 09, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Enzymatica AB and its competitors. This is 28% below median its historical median of 50.00. Over the past decade, Enzymatica AB's GF Score has ranged from 23.00 to 76.00.
Is Enzymatica AB's GF Score too high?
Enzymatica AB's current GF Score of 36 is 28% below median its 10-year median of 50.00. Over the past 10 years, this metric has ranged from a low of 23.00 to a high of 76.00. Overall, Enzymatica AB has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's GF Score compare to ZTS and UTHR?
Enzymatica AB's GF Score of 36 can be compared against companies in the Drug Manufacturers industry. Historically, Enzymatica AB's own GF Score has ranged from 23.00 to 76.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Enzymatica AB and its competitors. Enzymatica AB's current GF Score is 36, which is 28% below median its own 10-year median of 50.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.16, compared to a current price of €0.18 — trading 14.1% above its estimated fair value. The current GF Score is 36, which is 28% below median its 10-year median of 50.00. Enzymatica AB's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current GF Score is 36 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.18 is trading 14.1% above its estimated GF Value™ of €0.16. GuruFocus considers Enzymatica AB to be Modestly Overvalued.

Key valuation signals for FRA:EN9:

  • GF Score: 36 (28% below median its 10-year median of 50.00)
  • GF Value™: €0.16 vs. price of €0.18 (14.1% above fair value)
  • GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:Sweden
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
36GF Score

Get the complete analysis for FRA:EN9

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price
€0.16
GF Value